Belite Bio, INC 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

NASDAQ

31 Mar 2026

BLTE

Belite Bio, INC

20-F: Belite Bio's Tinlarebant Phase 3 Success, NDA Planned

Belite Bio announces highly significant Phase 3 DRAGON trial results for tinlarebant in STGD1, with an FDA NDA submission expected in Q2 2026, alongside ongoing GA trials and substantial capital raises.

NASDAQ

17 Mar 2025

BLTE

Belite Bio, INC

20-F: Belite Bio Files 20-F Annual Report for Fiscal Year 2024

Belite Bio, Inc. releases its 20-F filing, detailing financial results and operational activities for the year ended December 31, 2024.

NASDAQ

12 Mar 2024

BLTE

Belite Bio, INC

20-F: Belite Bio, Inc. Files 20-F Report: Details Financial Performance and Future Outlook

Belite Bio, Inc. releases its annual report on Form 20-F, providing a comprehensive overview of the company's financial results and strategic initiatives for the fiscal year ended December 31, 2023.